Angel Biotechnology Holdings plc (ABH.L) said it has signed a Framework Agreement with TransGenRx Inc. The purpose of the framework agreement is to outline the process whereby Angel will manage the development, scale up and manufacture of a recombinant protein product.
It is planned that the framework agreement will form the basis of future technical and commercial agreements whereby Angel will utilise its GMP facility at Cramlington to expedite and optimise the expression systems provided by TransGenRx Inc.
For comments and feedback: editorial@rttnews.com